Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
10/2001
10/31/2001DE10020505A1 RSV NS Proteine antagonisieren die Interferon (IFN) Antwort RSV NS proteins antagonize the interferon (IFN) response
10/31/2001DE10020500A1 Vector system for transforming eukaryotic cells, useful in gene therapy or vaccination, comprises invasive bacteria containing bacterial artificial chromosome
10/31/2001DE10019136A1 Polyamidnukleinsäure-Derivate, Mittel und Verfahren zu ihrer Herstellung Polyamide nucleic acid derivatives, means, and methods for their preparation
10/31/2001DE10019135A1 Polyamidnukleinsäure-Derivate, Mittel und Verfahren zu ihrer Herstellung Polyamide nucleic acid derivatives, means, and methods for their preparation
10/31/2001DE10019075A1 Verwendung von CD34 oder einem davon abgeleiteten Polypeptid als Zell-Oberflächen- bzw. Gentransfer-Marker Use of CD34 or a polypeptide derived as a cell-surface markers or gene transfer
10/31/2001CN1320163A Method for triggering apoptosis in cells
10/31/2001CN1320043A Mutant cholera holotoxin as an adjuvant
10/31/2001CN1320032A Alginate capsules for use in the treatment of brain tumor
10/31/2001CN1319605A Antitumour polypeptide and gene therapy vector composition
10/30/2001US6310197 Nucleotide sequences for use in treatment of alzheimer's disease
10/30/2001US6310196 DNA construct for immunization or gene therapy
10/30/2001US6310048 Antisense nucleotides coding given amino acid sequence of amyloid precursor protein (app) inhibit the expression of an amyloid beta protein (abp) portion of app while permitting expression of app polynucleotide 5' to the abp portion
10/30/2001US6310046 Encoded by isolated dna; diagnosis of and immunization against malaria
10/30/2001US6310045 Compositions and methods for cancer immunotherapy
10/30/2001US6310044 Oligonucleotide therapies for modulating the effects of herpesviruses
10/30/2001US6309878 Glucose-inducible recombinant viral vector
10/30/2001US6309876 Expression vector for propagation of cells in nervous system; for treating nervous system damage; gene therapy
10/30/2001US6309867 Polypeptide; for use in controlling aging and cancer
10/30/2001US6309866 6-phosphogluconate dehydrogenase
10/30/2001US6309856 Human MAD proteins and uses thereof
10/30/2001US6309853 Nucleotide sequences coding polypeptide associated with contolling bdy weight; for use in diagnosis and treatment of eating disorders
10/30/2001US6309830 Nucleotide sequence which encodes a synthetic transfer ribonucleic acid; for use as a tool in gene therapy
10/30/2001US6309819 Diagnostic and therapeutic system for Crohn's disease and Colitia ulcerosa
10/30/2001US6309651 A method of inhibiting, moderating or diagnosing pseudomonas aeruginosa infection is disclosed.
10/30/2001US6309645 A method of suppressing an immune response in a mammal.
10/30/2001US6309634 Methods of treating Parkinson's disease using recombinant adeno-associated vector (rAAV)
10/30/2001CA2170143C Cell death regulator
10/30/2001CA1341311C Transduced fibroblasts and uses therefor
10/26/2001CA2319149A1 Medicament for treatment of duchenne muscular dystrophy
10/25/2001WO2001079557A2 Gtp-binding protein useful in treatment and detection of cancer
10/25/2001WO2001079525A2 Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same
10/25/2001WO2001079524A2 Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof
10/25/2001WO2001079518A2 Codon optimisation for expression in retrovirus packaging cells
10/25/2001WO2001079510A1 Materials and methods relating to immune responses to fusion proteins
10/25/2001WO2001079502A2 Vectors for gene therapy
10/25/2001WO2001079495A1 Method of inducing tumor cell apoptosis using trail/apo-2 ligand gene transfer
10/25/2001WO2001079488A2 14257,protein kinase molecules and uses therefor
10/25/2001WO2001079480A1 Albumin fusion proteins
10/25/2001WO2001079471A2 Self-extinguishing recombinases, nucleic acids encoding them and methods of using the same
10/25/2001WO2001079469A2 Cloning of corynebacteriaceae histidine ammonia lyase and therapeutic uses
10/25/2001WO2001079455A1 Kv10.1, A NOVEL VOLTAGE-GATED POTASSIUM CHANNEL FROM HUMAN BRAIN
10/25/2001WO2001079445A2 Pluripotent cells comprising allogenic nucleus and mitochondria
10/25/2001WO2001079444A2 Albumin fusion proteins
10/25/2001WO2001079443A2 Albumin fusion proteins
10/25/2001WO2001079442A2 Albumin fusion proteins
10/25/2001WO2001079299A1 Enhancement of antibody-mediated immune responses
10/25/2001WO2001079286A2 Compositions and methods for the therapy and diagnosis of breast cancer
10/25/2001WO2001079284A2 Therapeutic compounds and methods for formulating v3, a versican isoform
10/25/2001WO2001079283A1 Modulating cell survival by modulating huntingtin function
10/25/2001WO2001079282A2 Molecules associated with human reproduction
10/25/2001WO2001079281A1 Sheep lice, bovicola ovis, allergen treatment
10/25/2001WO2001079274A2 Tuberculosis antigens and methods of use thereof
10/25/2001WO2001079273A2 Viruses comprising mutated ion channel protein
10/25/2001WO2001079271A1 Albumin fusion proteins
10/25/2001WO2001079258A1 Albumin fusion proteins
10/25/2001WO2001079253A1 Extracellular matrix polynucleotides, polypeptides, and antibodies
10/25/2001WO2001079249A2 Peptide nucleic acid derivatives with a negative charge, agents and methods for producing them
10/25/2001WO2001079216A2 Polyamide nucleic acid derivatives, agents and methods for producing them
10/25/2001WO2001078894A2 Novel human gene relating to respiratory diseases, obesity, and inflammatory bowel disease
10/25/2001WO2001078790A2 GENE THERAPHY FOR PULMONARY EDEMA USING ADENOVIRUS VECTORS ENCODING A β2ADRENERGIC RECEPTOR GENE
10/25/2001WO2001078789A2 Poliovirus replicons encoding therapeutic agents and uses thereof
10/25/2001WO2001078788A1 Cationic polymer-nucleic acid complexes and methods of making them
10/25/2001WO2001078771A1 Method of preventing or treating diabetes
10/25/2001WO2001078756A2 Agent for postoperative use after the removal of bone tumours
10/25/2001WO2001078753A2 Therapeutic uses for mesenchymal stromal cells
10/25/2001WO2001056596A8 Use of lysosomal acid lipase for treating atherosclerosis and related diseases
10/25/2001WO2001039786A3 New uses of suppressive macrophage activation factors
10/25/2001WO2001038584A3 Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof
10/25/2001WO2001036603A3 Recombinant adeno-associated virus virions for the treatment of lysosomal disorders
10/25/2001WO2001034781A3 Lytic enzymes useful for treating fungal infections
10/25/2001WO2001026679A3 T-cells and molecules involved in immune regulation
10/25/2001WO2001024684A3 Methods for treatment of solid tumors and metastasis by gene therapy
10/25/2001WO2001023597A3 Cell lines and constructs useful in production of e1-deleted adenoviruses in absence of replication competent adenovirus
10/25/2001WO2001023421A3 Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
10/25/2001WO2001022950A3 Diosolane nucleoside analogs for the treatment or prevention of viral infection
10/25/2001WO2001022092A3 Method to identify compounds which modulate fra-1 expression fils
10/25/2001WO2001021762A3 Method of decreasing cholesterol uptake
10/25/2001WO2001021220A3 Bioprosthetic heart valves
10/25/2001WO2001014579A3 Compositions and methods for delivery of an agent using attenuated salmonella containing phage
10/25/2001WO2001012790A3 Isomerase proteins
10/25/2001WO2001012126A3 Cardiomyocyte regeneration
10/25/2001WO2000047104A3 Antagonists of hmg1 for treating inflammatory conditions
10/25/2001WO2000040605A9 Compositions and methods relating to cyclic compounds that undergo nucleotide base pair-specific interactions with double-stranded nucleic acids
10/25/2001US20010034436 Polynucleotide and polypeptides, screening for antibiotic activity, Staphylococcus
10/25/2001US20010034334 Genetic engineered polypeptide
10/25/2001US20010034330 Administering a mixture containing dinucleotide
10/25/2001US20010034329 Nucleic acids
10/25/2001US20010034327 Suppression of inhibitors
10/25/2001US20010034062 For engineering cells for delivery of antibodies to combat respiratory diseases, viral infection, asthma, allergy, and macular degeneration
10/25/2001US20010034061 Culturing a population of mammalian cells capable of forming a solid tissue in a medium with oxygen level selected to enhance survival of the stem or progenitor cell type; subatmospheric oxygen; drug screening
10/25/2001US20010034044 Genomic sequences for protein production and delivery
10/25/2001US20010033845 Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence
10/25/2001US20010033836 Transgenic autologous T-cell therapy in humans, and related compositions and kits
10/25/2001US20010033834 Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof
10/25/2001US20010033833 Side effect reduction
10/25/2001DE10020125A1 Agent for stimulating bone regrowth, useful as insert after surgery for bone cancer, comprises single sequence expressing a fusion of growth factor and protease inhibitor
10/25/2001CA2747325A1 Albumin fusion proteins
10/25/2001CA2409190A1 Poliovirus replicons encoding therapeutic agents and uses thereof
10/25/2001CA2406955A1 Sheep lice, bovicola ovis, allergen treatment
10/25/2001CA2406590A1 Agent for postoperative use after the removal of bone tumours
1 ... 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 ... 870